Inhibitors of interleukin-1.beta. converting enzyme

Details Inhibitors of interleukin-1.beta. converting enzyme Inhibitors of interleukin-1.beta. converting enzyme

1994-06-17

1998-05-26

Huff, Sheela

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 16, 514 17, 514 19, 530329, 530330, 530331, A61K 3800, C07K 500, C07K 700, C07K 1700

Patent

active

057564663

ABSTRACT:
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

REFERENCES:
patent: 4276298 (1981-06-01), Jones et al.
patent: 4369183 (1983-01-01), Jones et al.
patent: 4499295 (1985-02-01), Mueller et al.
patent: 4551279 (1985-11-01), Mueller et al.
patent: 4584397 (1986-04-01), Mueller et al.
patent: 4968607 (1990-11-01), Dower et al.
patent: 5008245 (1991-04-01), Digenis et al.
patent: 5055451 (1991-10-01), Krantz et al.
patent: 5081228 (1992-01-01), Dower et al.
patent: 5158936 (1992-10-01), Krantz et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5411985 (1995-05-01), Bills et al.
patent: 5416013 (1995-05-01), Black et al.
patent: 5430128 (1995-07-01), Chapman et al.
patent: 5434248 (1995-07-01), Chapman et al.
patent: 5462939 (1995-10-01), Dolle et al.
patent: 5486623 (1996-01-01), Zimmerman et al.
patent: 5498695 (1996-03-01), Daumy et al.
patent: 5552400 (1996-09-01), Dolle et al.
patent: 5639745 (1997-06-01), Dolle et al.
patent: 5670494 (1997-09-01), Dolle
Spatola, A.F., in "Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins," ch. 5, pp. 267-281, Weinstein, B., ed., Marcel Dekker, Inc., New York (1993).
Fan, T.-P.D. et al., "Stimulation of Angiogenesis by Substance P and Interleukin-1 in the Rat and Its Inhibition by NK.sub.1 or Interleukin-1 Receptor Antagonists" Br. J. Pharmacol., 110, pp. 43-49 (1993).
Fauszt, I. et al., "Inhibition of Interleukin-1.beta. Converting Enzyme by Peptide Derivatives" Proc. of the 13th Am. Peptide Symp., Jun. 20-25, 1993, Hodges, R.S. and Smith, J.A., Eds., Peptides, pp. 589-591 (1994).
Hanessian, S. et al., "Design and Synthesis of a Prototype Model Antagonist of Tachykinin NK-2 Receptor" Bioorg. Med. Chem. Lett., 11, pp. 1397-1400 (1994).
Mjalli, A.M.M. et al., "Phenylalkyl Ketones as Potent Reversible Inhibitors of Interkeukin-1.beta. Converting Enzyme" Bioorg. Med. Chem. Lett., 3, pp. 2689-2692 (1993).
Mullican, M.D. et al., "The Synthesis and Evaluation of Peptidyl Aspartyl Aldehydes as Inhibitors of ICE" Bioorg. Med. Chem. Lett., 4, pp. 2359-2364 (1994).
Robinson, R.P. and Donahue, K.M., "Synthesis of a Peptidyl Difluoro Ketone Bearing the Aspartic Acid Side Chain: An Inhibitor of Interleukin-1.beta. Converting Enzyme" J. Org. Chem., 57, pp. 7309-7314 (1992).
Salvatore, M.J. et al., "L-741,494, A Fungal Metabolite that is an Inhibitor of Interleukin-1.beta. Converting Enzyme" J. Nat. Prods., 57, pp. 755-760 (1994).
D. Alberg & S. Schreiber, "Structure-Based Design of a Cyclophilin-Calcineurin Bridging Ligand", Science, 262, pp. 248-250 (1993).
P. Andrews, "Functional Groups, Drug-Receptor Interactions and Drug Design", Trends Pharmacol. Sci., 7, pp. 148-151 (1986).
K. Appelt et al., "Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis", J. Med. Chem., 34, pp. 1925-1934 (1991).
E. Baker & J. Drenth, "The Thiol Proteases: Structure and Mechanism", in Biological Macromolecules and Assemblies, 3, pp. 313-368 (F. Jurnak & A. McPherson eds., 1987).
J. Baldwin et al., "Thienothiopyran-2-sulfonamides: Novel Topically Active Carbonic Anhydrase Inhibitors for the Treatment of Glaucoma", J. Med. Chem., 32, pp. 2510-2513 (1989).
M. Barinaga, "Death Gives Birth to the Nervous System. But How?". Science, 259, pp. 762-763 (1993).
P. Bartlett et al., "Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules", Molecular Recognition: Chemical and Biochemical Problems, 78, pp. 182-196 (1989).
P. Bender & J. Lee, "Pharmacological Modulation of Interleukin-1", Annu. Rep. Med. Chem., 25, pp. 185-193 (1989).
R. Black et al., "Activation of Interleukin-1.beta. by a Co-induced Protease", FEBS Lett, 247, pp. 386-390 (1989).
H. Bohm, "The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors", J. Comput. Aided Mol. Des., 6, pp. 61-78, (1992).
J. Breitner et al., "Inverse Association of Anti-inflammatory Treatments and Alzheimer's Disease: Initial Results of a Co-twin Control Study", Neurology, 44, pp. 227-232 (1994).
B. Brooks et al., "CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations", J. Comput. Chem., 4, pp. 187-217 (1983).
A. Brunger, "Extension of Molecular Replacement: A New Search Strategy Based on Patterson Correlation Refinement", Acta Crystallogr. A, 46, pp. 46-57 (1990).
A. Brunger & A. Krukowski, "Slow-Cooling Protocols for Crystallographic Refinement by Simulated Annealing", Acta Crystallogr. A, 46, pp. 585-593 (1990).
U. Burkett & N. Allinger, "Methods for the Computation of Molecular Geometry" in Molecular Mechanics, pp. 59-78 (1982).
M. Carson, "Ribbons 2.0", J. App. Crystallogr. 24, pp. 958-961 (1991).
F. Casano et al., "The Structure and Complete Nucleotide Sequence of the Murine Gene Encoding Interleukin-1.beta. Converting Enzyme (ICE)", Genomics, 20, pp. 474-481 (1994).
D. Cerretti et al., "Molecular Cloning of the Interleukin-1.beta. Converting Enzyme", Science, 256, pp. 97-100 (1992).
K. Chapman, "Synthesis of a Potent, Reversible Inhibitor of Interleukin-1.beta. Converting Enzyme", Bioorg. Med. Chem. Lett., 2, pp. 613-618 (1992).
N. Cohen, "Drug Design in Three Dimensions", Advances in Drug Research, 14, pp. 41-145 (1985).
N. Cohen, "Rational Drug Design and Molecular Modeling", Drugs of the Future, 10, pp. 311-328 (1985).
N. Cohen et al., "Molecular Modeling Software and Methods for Medicinal Chemistry", J. Med. Chem., 33, pp. 883-894 (1990).
D. Davies & D. Segal, "Protein Crystallization: Micro Techniques Involving Diffusion", Methods Enzymol., 22, pp. 266-269 (1971).
K. Dill, "Dominant Forces in Protein Folding", Biochemistry, 29, pp. 7133-7155 (1990).
C. Dinarello, "Role of Interleukin-1 in Infectious Diseases", Immunol. Rev., 127, pp. 119-146 (1992).
C. Dinarello et al., "Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome", J. Am. Med. Assoc., 269, pp. 1829-1835 (1993).
R. Dolle et al., "P.sub.1 Aspartate-Based Peptide .alpha.-((2,6-Dichlorobenzoyl)oxy)methyl Ketones as Potent Time-Dependent Inhibitors of Interleukin-1.beta. Converting Enzyme", J. Med. Chem., 37, pp. 563-564 (1994).
S. Ealick et al., "Application of Crystallographic and Modeling Methods in the Design of Purine Nucleoside Phosphorylase Inhibitors", Proc. Natl. Acad. Sci. USA, 88, pp. 11540-11544 (1991).
P. Edwards et al., "Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl .alpha.-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole", J. Am. Chem. Soc., 114, pp. 1854-1863 (1992).
H. Eklund et al., "Three-dimensional Structure of Horse Liver Alcohol Dehydrogenase at 2.4 .ANG. Resolution", J. Mol. Biol., 102, pp. 27-50 (1976).
J. Erickson et al., "Design, Activity, and 2.8 .ANG. Crystal Structure of a C.sub.2 Symmetric Inhibitor Complexed to HIV-1 Protease", Science, 249, pp. 527-533 (1990).
V. Gagliardini et al., "Prevention of Vertebrate Neuronal Death by the crmA Gene", Science, 263, pp. 826-828 (1994).
T. Geiger et al., "Neutralization of Interleukin-1.beta. Activity in vivo with a Monoclonal Antibody Alleviates Collagen-induced Arthritis in DBA/1 Mice and Prevents the Associated Acute-phase Response", Clin. Exp. Rheumatol., 11, pp. 515-522 (1993).
A. Giannis & T. Kolter, "Peptidomimetics for Receptor Ligands-Discovery, Dev

Affiliated with

Also associated with

Rating

Inhibitors of interleukin-1.beta. converting enzyme does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of interleukin-1.beta. converting enzyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of interleukin-1.beta. converting enzyme will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1960111